This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functionsin vitroand/orin vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing optionally wherein these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing are used in therapeutic regimens that further include the administration of other therapeutic agents, e.g., mitochondrial inhibitors and/or biguanides or small molecule MCT1 inhibitors.本發明概言之係關於抗體及其抗原結合片段，例如人類化、嵌合及人類抗體及其抗原結合片段，以及融合蛋白；含有此等抗體及其抗原結合片段以及融合蛋白之組合物，其中此等抗體及其抗原結合片段以及融合蛋白特異性結合至MCT1，例如人類或非人類MCT1，且在活體外及/或在活體內拮抗、抑制或阻斷一或多種MCT1相關之功能。本發明亦係關於該等抗MCT1抗體、抗原結合片段、融合蛋白及含有其之組合物之治療性及診斷性用途，視情況其中該等抗MCT1抗體、抗原結合片段、融合蛋白及含有其之組合物用於治療性方案中，該等治療性方案進一步包括投與其他治療劑，例如粒線體抑制劑及/或雙胍或小分子MCT1抑制劑。
